Congratulations on your OTCQX listing under the symbol “CTABF”. Can you tell me a little bit about what that means for Canntab and for investors in the United States?
Historically, it’s been difficult for US investors to take ownership of our company, that changes with our upgrade to the OTCQX Best Market. With this increased visibility and accessibility to residence of the United States we are now looking at beginning an awareness campaign to drive interest in our offering while increasing trading volume.
Jeff, I also want to remind our readers how we have said from the onset that hemp will dwarf cannabis (yes, hemp is a sativa but we distinguish because of the regulations and legal status) … and from there how it is difficult to distinguish oneself from competitors with a near homogenous commodity or product. You have done so with your capsules … but I believe also with your organic hemp deal … would you agree and why is that?
We’d like to avoid too much talk about our hemp deal. It’s great for us because we have secured a good supply of hemp at a great price but we want to be known as Pharma not Farmers as so we typically avoid discussing this when we are given a limited time or when we want the focus to be on investing.
Our readers know that unlike many … we do not hold back and we ask the tough questions so I think our readers and you saw this one coming. In December 2018 you announced an agreement with “leading Orthopaedic surgeon Dr. Don Garbuz, M.D. for a clinical research trial of Canntab’s Tablets” … trials take time and we understand that … so to the degree that you can say … how is this going and when should preliminary results be released to the public?
93